What is the efficacy of adjuvant therapies for the treatment of cutaneous melanoma?

Updated: Oct 13, 2020
  • Author: Susan M Swetter, MD; Chief Editor: Dirk M Elston, MD  more...
  • Print

Numerous adjuvant therapies have been investigated for the treatment of localized cutaneous melanoma following complete surgical removal. No overall survival (OS) benefit has been demonstrated for adjuvant chemotherapy, nonspecific (passive) immunotherapy (including interferon [IFN] and now ipilimumab), radiation therapy, retinoid therapy, vitamin therapy, or biologic therapy. [78] IFN alfa-2b was the first US Food and Drug Administration (FDA)‒approved adjuvant therapy for high-risk melanoma (currently defined as stages IIB, IIC, and III), which is associated with a 40-80% chance of relapse and death.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!